| 韦知樱 陈萍 温小萍 覃业语 王敏.阿托伐他汀对大脑中动脉支架置入后患者血脂、血清CRP及
脑缺血性不良事件的影响[J].现代生物医学进展英文版,2014,14(35):6960-6962. |
| 阿托伐他汀对大脑中动脉支架置入后患者血脂、血清CRP及
脑缺血性不良事件的影响 |
| Effects of Atorvastatin on the Blood Lipids, SerumCRP and CerebralIschemic Adverse Events of Patients with Middle Cerebral Artery Stenting |
| |
| DOI： |
| 中文关键词: 阿托伐他汀 大脑中动脉支架置入术 血脂 血清C- 反应蛋白 |
| 英文关键词: Atorvastatin Middle cerebral artery stenting Blood lipids SerumC- reactive protein |
| 基金项目: |
|
| Hits: 847 |
| Download times: 834 |
| 中文摘要: |
| 目的：探讨阿托伐他汀对大脑中动脉支架置入后患者血脂、血清C- 反应蛋白（CRP）及脑缺血性不良事件的影响。方法：选
择本院收治的60 例行大脑中动脉支架置入术后的患者，采用随机序号的方式将其分为观察组和对照组各30 例，其中对照组给
予口服拜阿司匹林和硫酸氢氯吡格雷进行治疗，观察组在对照组基础上加服阿托伐他汀进行治疗，对两组治疗后6 个月、12 个月
时患者血脂、血清C-反应蛋白（CRP）及脑缺血性不良事件发生率进行对比分析。结果：观察组在治疗后6 个月时LDL-C、TC、TG
及CRP 含量与治疗前和对照组比较显著下降，比较差异均有统计学意义（P<0.05）；观察组患者在治疗后的12 个月时LDL-C、
TC、TG及CRP含量亦明显低于治疗前和对照组，比较差异均有统计学意义（P<0.05）；观察组不良事件发生率为10%，明显低于
对照组不良事件发生率的30%，两组比较差异有统计学意义（P<0.05）。结论：阿托伐他汀对不仅可有效改善大脑中动脉支架置入
术后患者的血脂、血清C-反应蛋白（CRP）的各项指标水平，而且还能有效的降低脑缺血性不良事件的发生。 |
| 英文摘要: |
| Objective:To investigate the effects of atorvastatin on the blood lipids, serum C- reactive protein (CRP) and cerebral
ischemic adverse events of patients with middle cerebral artery stenting.Methods:60 cases of patients with middle cerebral artery
stenting were selected and were divided into observation group(n=30) and control group(n=30) via random number approach, the control
group received oral Aspirin chlorine and hydrogen sulfate clopidogrel treatment while the observation group were served basic treatment
as the control group and the additional treatment with atorvastatin. The blood lipids, serum C- reactive protein (CRP), and the incidence
of cerebral ischemic adverse events were analyzed 6 months and 12 months after treatment.Results:The LDL-C, TC, TG and CRP levels
of the observation group after 6 months of treatment significantly decreased compared with pre-treatment and the control group, and the
differences were statistically significant (P<0.05); The LDL-C,TC,TG and CRP levels of the observation group after 12 months of
treatment was also significantly decreased compared with pre-treatment and the control group, the differences were both statistically
significant (P<0.05); The incidence of adverse events in observation group was 10%, significantly lower than that (30%) in the control
group, the difference was statistically significant (P<0.05).Conclusion:The atorvastatin can not only effectively improve blood lipids,
serum indicators of C-reactive protein (CRP) of patients with middle cerebral artery stenting, but also effectively reduce the brain
ischemic adverse events. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
